Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Mar 7, 2007
Trial Information
Current as of May 28, 2025
Terminated
Keywords
ClinConnect Summary
* Principal Objective : Our study examined one main question: Are there difference in efficacy between droperidol IV 0.625 mg or 2.5 mg for the treatment or prophylaxis of PONV to surgical patient undergoing thyroid surgery when they receive it 30 min before emergence from general anaesthesia?
* Secondary Objective :
* comparison of the % of patients in every group:
* having a complete control of their nausea
* requiring secondarily the appeal to another anti-emetic treatment in postoperative
* presenting an Adverse event
* Compare score of sedation in ach groups
* Evalu...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female
- • More than 18 years old
- • Patients scheduled for thyroid surgery
- • Simplified Apfel score ≥ 2
- • ASA score : 1-2
- • Informed consent obtained from the patient
- • Women able to procreate must have a reliable contraceptive method
- Exclusion Criteria:
- • Age \< 18 years old
- • Male
- • Obesity
- • Has a severe depressive syndrome
- • Pregnancy women
- • Trouble with cardiac rate
- • Alcoholism
- • Contra-indication for Droperidol prescription
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pessac Cedex, , France
Patients applied
Trial Officials
Gérard JANVIER, MD
Study Director
University Hospital, Bordeaux
Laure BAUDOUIN, Dr
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials